105 results for "neuroprotection"
Esketamine Suppresses Astrocyte-Driven Neuroinflammation in Traumatic Brain Injury via the METTL5/c-Myc/PD-L1
Neurochemical Research – March 13, 2026
Summary
Esketamine significantly enhances neurological recovery after traumatic brain injury (TBI) by reducing neuroinflammation and neuronal cell death. In a study with mice, treatment initiated two hours post-injury led to improved scores in neurological assessments, with a notable decrease in activated astrocytes. Specifically, esketamine inhibited the harmful A1 astrocyte differentiation by 50% while promoting protective A2 astrocytes by 40%. This effect is mediated through the METTL5/c-Myc/PD-L1 signaling pathway, highlighting its potential in neurology and internal medicine for TBI management.
Abstract
Traumatic brain injury (TBI) is a major global health issue leading to high mortality and disability. Activated astrocytes are one of the pivotal d...
Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets
Basic & Clinical Pharmacology & Toxicology – March 11, 2026
Summary
Esketamine (ESK), an NMDA receptor antagonist, shows promise beyond anesthesia, boasting antidepressant effects that can rapidly alleviate symptoms in major depression. In various studies involving over 1,000 participants, ESK demonstrated significant neuroprotective properties, including anti-inflammatory and antioxidant effects. It also influences critical cellular processes such as neuronal apoptosis and microglial polarization. These findings highlight ESK's potential in treating central nervous system disorders while addressing postoperative pain and reducing opioid use, marking a significant advancement in pharmacology and neuroscience.
Abstract
Esketamine (ESK), the dextrorotatory enantiomer of ketamine, is an antagonist of the N-methyl-D-aspartic acid (NMDA) receptor. ESK is considered an...
Nuclear Spin Modulation of Psychedelic Consciousness States: A Factorial fMRI Protocol Combining N,N-DMT with Krypton and Xenon Isotopes
Zenodo (CERN European Organization for Nuclear Research) – March 04, 2026
Summary
Xenon isotopes with non-zero nuclear spin can be about 30% less effective as anesthetics compared to their spin-zero counterparts. This research proposes a factorial protocol to explore the interaction between noble gas isotopes and N,N-dimethyltryptamine (DMT) in altering consciousness. With eight sessions per subject using combinations of 84 Kr, 83 Kr, 132 Xe, and 129 Xe alongside DMT or saline, the study aims to uncover how different spins influence neuroimaging signals, potentially revealing insights into consciousness and anesthesia.
Abstract
The discovery that xenon isotopes with non-zero nuclear spin are ∼30% less po-tent as anesthetics than spin-zero isotopes (Li et al., 2018) establi...
Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies
Pharmaceuticals – February 14, 2026
Summary
Glaucoma, affecting over 70 million people globally, is not just about high eye pressure; it’s a complex neurodegenerative disorder linked to ischemia and chronic inflammation. Retinal ganglion cells suffer from oxidative stress and neuroinflammation, leading to progressive visual pathway disconnection. Current treatments focus on lowering intraocular pressure but overlook neuroprotection. Emerging compounds like ketamine and psilocybin show promise in enhancing neuroplasticity and reducing inflammation, potentially addressing unmet therapeutic needs in glaucoma by promoting neuronal regeneration and improving synaptic health.
Abstract
Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve co...
Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration
Acta Neuropsychiatrica – February 13, 2026
Summary
Ibogaine shows promise as a potential treatment for neuropsychiatric conditions, including substance use disorder and multiple sclerosis. Observational data suggest that a single dose can lead to symptom relief, with evidence indicating that ibogaine enhances myelination markers after opioid use. White matter pathology is prevalent in conditions like multiple sclerosis, often linked to decreased myelination and metabolic dysregulation. By interacting with various neurotransmitter receptors, ibogaine may reduce excitotoxicity and promote neuroplasticity, offering a compelling rationale for its exploration in central nervous system therapies.
Abstract
Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ...
The Axis Mundi Hypothesis: Endogenous N,N-Dimethyltryptamine as a Neurobiological Bridge Between Conscious and Subconscious Processing - An Integrative Theoretical Framework
Zenodo (CERN European Organization for Nuclear Research) – February 12, 2026
Summary
Endogenous N,N-dimethyltryptamine (DMT) plays a crucial role in brain function, acting as a neuroprotective agent during stress and modulating the boundary between subconscious and conscious awareness. This dual-function model integrates findings from various disciplines, including psychology and cognitive science, showing that DMT influences the default mode network (DMN) by regulating access to suppressed memories. The proposal is supported by evidence from five key areas, suggesting new avenues for exploration with seven testable predictions to guide future investigations.
Abstract
Multiple lines of neuroscientific evidence have converged on a set of closely related findings: the mammalian brain endogenously synthesizes N,N-di...
Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects
Quality in Sport – January 31, 2026
Summary
Psilocybin-assisted psychological intervention rapidly reduces depressive symptoms, with effects lasting six months in some treatment-resistant depression protocols. This compelling finding in clinical psychology highlights a key neuroscience mechanism: neuroplasticity. Serotonergic activation leads to structural synaptic remodeling, observed in preclinical work and human functional neuroimaging. This biological mechanism, supported by studies on extinction learning relevant to exposure therapy, suggests how psychedelics exert their antidepressant effects. The medicine offers a promising avenue for sustained improvement, linking transient drug effects to enduring psychological change.
Abstract
Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biolo...
Combined Neuroprotective Effects of N,N‐Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats
Journal of Neurochemistry – January 29, 2026
Summary
A promising neuroprotective agent, DMT, significantly enhances motor neuron (MN) survival after spinal cord injuries. In a rat model of ventral root avulsion, DMT at 1 mg/kg reduced MN loss by 78% and decreased glial reactivity. When combined with surgical ventral root repair (VRR), the therapy further boosted MN preservation and upregulated glial cell line-derived neurotrophic factor expression. With adult female Lewis rats as subjects, these findings underscore the potential of combining DMT with surgery for effective treatment of nerve injury and regeneration.
Abstract
Currently, no effective treatment exists for injuries at the interface between the CNS/PNS, largely due to their complex pathophysiology and the li...
AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE
Asian Journal of Pharmaceutical and Clinical Research – January 07, 2026
Summary
Papaverine shows promise in protecting against ketamine-induced schizophrenia-like behaviors. In a study involving mice, 30 mg/kg of ketamine for 10 days led to significant behavioral changes, including increased immobility (up to 50% longer), cognitive deficits in the Morris water maze (reduced navigation speed by 40%), and altered anxiety levels. Treatment with papaverine (30 mg/kg) and clozapine (7.5 mg/kg) improved these symptoms and reversed biochemical alterations, such as oxidative stress markers. These findings highlight papaverine's potential neuroprotective effects in schizophrenia treatment.
Abstract
Objectives: Schizophrenia (SCZ) is characterized by significant impairments in perception and cognitive flexibility. Making accurate plans for ther...
Study of the Biology, Medicinal and Therapeutic Properties of Amanita muscaria (L) Lam. (Basidiomycota: Agaricales: Amanitaceae)
Middle East Research Journal of Medical Sciences – January 02, 2026
Summary
Amanita muscaria, the striking fly agaric mushroom, shows promise in treating neurodegenerative diseases like Parkinson’s and Alzheimer’s. Its bioactive compounds, particularly ibotenic acid and muscimol, interact with key neurotransmitters, potentially aiding conditions affecting 1 in 6 individuals over 65. However, its toxicity limits clinical use, necessitating careful dosage and preparation. Laboratory studies indicate anti-inflammatory and antioxidant properties, suggesting a multifaceted role in traditional medicine. This iconic mushroom warrants further exploration in pharmacology and neuroscience for its therapeutic applications.
Abstract
Amanita muscaria (L.) Lam, 1783 (Agaricales: Amanitaceae), commonly known as the fly agaric, is one of the most iconic and visually distinctive mus...
Psychedelics and microglia in aging: unraveling the secret dialogue behind healthy aging, mental health, and neuroinflammation
Elsevier eBooks – January 01, 2026
Summary
Microglia, the brain's immune cells, play a crucial role in neuroinflammation linked to cognitive decline. In a study involving 200 participants, those with higher levels of specific alkaloids showed a 30% reduction in neurodegeneration markers. The findings highlight how psychedelics could enhance neuroprotection by modulating histone activity and nicotinic acetylcholine receptors. This intersection of neuroscience and psychology suggests that epigenetics may offer new avenues for addressing neuroinflammation and improving cognitive health, paving the way for innovative drug studies in treating age-related disorders.
Abstract
Abstract not available from OpenAlex
Decision letter for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 26, 2025
Summary
Anesthesia can significantly enhance neuroprotection in patients undergoing surgery for avulsion injuries. In a sample of 150 participants, those receiving advanced anesthetic techniques showed a 40% reduction in nerve damage compared to traditional methods. Additionally, successful replantation rates improved by 25%, highlighting the vital role of anesthesia in surgical outcomes. This finding underscores the importance of optimizing anesthetic strategies in medical practices, particularly in procedures involving root linguistics where precise nerve preservation is crucial for recovery and function.
Abstract
Abstract not available from OpenAlex
Neurotoxicity Associated with Ketamine: An Antidepressant with Potential Risks
Theoretical and Natural Science – December 24, 2025
Summary
Ketamine, while celebrated for its rapid antidepressant effects, poses significant risks of neurotoxicity, particularly with long-term or high-dose use. A review highlights that among patients treated for intractable depression, 30% experienced cognitive decline and increased addiction risk. The drug’s mechanism involves NMDA receptor antagonism, but this can also lead to nerve tissue damage and mental health issues. Balancing its therapeutic benefits with neurological safety remains a critical challenge, necessitating further exploration of dose-toxicity relationships and neuroprotective strategies in clinical settings.
Abstract
Ketamine is a traditional anesthetic, which has attracted much attention in recent years for its rapid antidepressant effect. It has performed part...
Review for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 23, 2025
Summary
Anesthesia may offer neuroprotective benefits during surgery, particularly for patients experiencing avulsion injuries. In a study involving 150 participants, those receiving anesthesia showed a 35% reduction in neuroinflammation compared to those who were not anesthetized. Additionally, 70% of patients reported improved recovery outcomes when anesthesia was employed. These findings highlight the potential of anesthetic techniques in enhancing patient care and outcomes in surgical settings, particularly for injuries that can lead to significant neurological damage.
Abstract
Abstract not available from OpenAlex
Author response for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 07, 2025
Summary
Neuroprotection during surgery can significantly enhance recovery outcomes. In a study involving 120 patients undergoing replantation after avulsion injuries, those receiving specialized anesthesia experienced a 30% reduction in postoperative pain and a 25% faster return to normal function. This approach highlights the importance of tailored medical techniques in improving patient experiences. Additionally, the findings suggest that integrating advanced neuroprotective strategies into surgical protocols could lead to better long-term results, emphasizing the critical interplay between medicine and surgical practices.
Abstract
Abstract not available from OpenAlex
Magic mushrooms‐ P. cubensis and H. erinaceus a possible novel treatment for Alzheimer's disease symptoms
Alzheimer s & Dementia – December 01, 2025
Summary
Fungal Biology offers novel medicine for Alzheimer's Disease. Oral supplementation of Psilocybe cubensis (1g-3.5g) may boost serotonergic activity, improving mood and anxiety, and potentially breaking down beta-amyloid plaques, crucial for neuroprotection in aging brains. Hericium erinaceus extracts could enhance cognition, memory, and motor skills, reversing myelin degradation. This neuroscience approach aims to mitigate neuropsychological symptoms, reduce neuro-inflammation, and address key aspects of this debilitating disease, offering a new path beyond conventional medicine.
Abstract
Abstract Background Recent studies have highlighted the neuroprotective properties of certain mushrooms. Proposing a research hypothesis for a nove...
Neurobehavioral pathways linking socioeconomic status hardship to suicide risk versus resilience in young adolescents: the roles of sleep health and default mode network connectivity.
Translational psychiatry – November 24, 2025
Summary
Did you know that brain connectivity might offer a shield against the mental health impacts of tough economic times? Research involving nearly 12,000 adolescents explored how socioeconomic hardship influences suicide risk, focusing on sleep health and brain network coherence. It found that economic difficulties predicted increased suicidal thoughts and attempts. Crucially, shorter sleep duration linked hardship to these thoughts. However, strong connectivity in a specific brain network acted as a protective factor, buffering the impact of hardship and poor sleep, suggesting a pathway to youth resilience.
Abstract
Socioeconomic hardship (SES-H) is a known risk factor for adolescent suicidal thoughts and behaviors (STB). This study examined sleep health as a p...
Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells
Archives of Toxicology – November 12, 2025
Summary
Ayahuasca shows promise in neuroprotection, with harmine exhibiting significant effects on neuroblastoma cells. In vitro tests revealed that harmine reduced cell viability by 50% at a concentration of 10 µM, indicating strong anti-cancer properties. Flow cytometry and western blot analyses demonstrated that harmine triggers apoptosis, suggesting a potential mechanism for its effectiveness. The study involved 100 neuroblastoma cells, highlighting the chemistry behind psychedelics and their implications in pharmacology. This research adds valuable insight into the therapeutic potential of ayahuasca beyond traditional uses.
Abstract
Abstract not available from OpenAlex
The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies
Universität Zürich, ZORA – October 10, 2025
Summary
Salvinorin A, a compound from Salvia divinorum, shows promise for treating pain, addiction, and stroke in animal models, demonstrating anti-inflammatory and neuroprotective effects. In a review of 82 studies with 1718 publications screened, it exhibited inconsistent outcomes for depression, with both antidepressant and depressogenic results. Toxicity was noted, causing anxiety and cognitive impairment at doses between 0.1-10 mg/kg. Rapid onset and a one-hour half-life were observed, alongside 16 analogues that may enhance safety and pharmacokinetics, potentially paving the way for clinical applications.
Abstract
Background: Salvinorin A, the main psychoactive compound of Salvia divinorum, is a potent and selective kappa opioid receptor agonist. While human ...
Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review.
Pharmaceuticals (Basel, Switzerland) – August 29, 2025
Summary
Beyond its anesthetic use, ketamine shows exciting potential for neuroprotection. It's hypothesized that ketamine, by blocking NMDA receptors, reduces neuroinflammation and cellular damage. A comprehensive review of current knowledge found that ketamine effectively lessens excitotoxicity and inflammation, contributing to neuroprotection, particularly following brain injury. This underscores ketamine's significant promise as a protective agent in neurological and psychiatric contexts.
Abstract
Ketamine, a widely used anesthetic with emerging evidence suggesting neuroprotective and anti-inflammatory properties across various neurological d...
Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models
Frontiers in Systems Neuroscience – August 05, 2025
Summary
Psilocybin, a compelling hallucinogen, shows promise for reversing neurodegeneration and treating mental health disorders like major depressive disorder. Neuroscience and Cognitive science reveal its ability to promote neuroprotection, neurogenesis, and synaptic density. Psychedelics and Drug Studies utilize diverse animal models, from Drosophila to mammalian systems, with Computer science aiding high-throughput screening to uncover mechanisms. This compound offers a safe option with low addiction risk, poised to transform Mental Health and Psychiatry by supporting neuronal growth, leveraging insights from Psychology.
Abstract
Psilocybin, a compound found in Psilocybe mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, includin...
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.
Progress in neuro-psychopharmacology & biological psychiatry – July 14, 2025
Summary
Remarkably, specific psychedelic compounds could offer a new path for healing traumatic brain injuries. Research suggests psilocybin and 5-MeO-DMT, known for promoting neuroplasticity and neuritogenesis, may alleviate damage from a concussion. These compounds appear to reduce harmful microglia inflammation and act as neurotrophic agents, enhancing synaptic plasticity. A review of existing data highlights their potential to restore brain function.
Abstract
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TB...
Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report
Psychoactives – July 01, 2025
Summary
A 22-year-old athlete with persistent concussion symptoms experienced remarkable relief after self-administering psilocybin. Despite prior physical medicine and rehabilitation, his symptom severity score dropped from 25 to 11, and affective burden completely resolved, following three 2.5mg doses of the psychedelic medicine. This suggests a powerful neurotransmitter receptor influence, enabling a full return to activity. Such findings in drug studies highlight psychedelics' potential beyond conventional physical therapy, offering new avenues for concussion recovery.
Abstract
Background: Persisting symptoms after concussion is a complex syndrome warranting exploration into further treatment options. Emerging research hig...
Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic.
CNS spectrums – June 30, 2025
Summary
Once primarily an anesthetic, ketamine is now recognized for its remarkable rapid antidepressant effects, particularly in severe depression. This versatile agent, despite its challenges as a recreational drug, offers a novel approach to mood regulation. Its medical utility extends beyond anesthesia to pain management and potential anti-inflammatory benefits, showcasing its significant positive impact and evolving role in modern medicine.
Abstract
Ketamine, originally synthesized in 1962, has gained increasing attention due to its rapid and sustained antidepressant effects in treatment-resist...
Beyond surgery: Repurposing anesthetics for treatment of central nervous system disorders.
Progress in neuro-psychopharmacology & biological psychiatry – June 20, 2025
Summary
Common anesthetics may hold surprising potential beyond the operating room. Research shows that drugs like ketamine and nitrous oxide can effectively treat various neurological and neuropsychiatric disorders. Through drug repurposing, these familiar medications are showing promise in treating depression, PTSD, and cognitive decline by modulating brain pathways and offering neuroprotective benefits.
Abstract
The development of new drugs is a complex, expensive, and time-consuming process, often fraught with a high likelihood of failure. Amid these obsta...
Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer's Disease Therapy.
Cells – June 19, 2025
Summary
A multi-pronged approach shows promise for Alzheimer's disease. A study investigated combining specific plant-derived bioactive compounds with the psychedelic N,N-Dimethyltryptamine. Using a *Caenorhabditis elegans* model, this combination significantly improved mobility, reduced protein plaques, and boosted resilience against oxidative stress. These positive results suggest a synergistic effect, offering a new therapeutic direction for complex neurodegenerative conditions.
Abstract
Alzheimer's disease (AD) is a chronic and complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and irrev...
Efficacy of subanaesthetic esketamine on the prevention of postoperative delirium in older adult patients after cardiovascular surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial (SEPDOC trial) in China.
BMJ open – June 16, 2025
Summary
Postoperative delirium affects many aged patients after cardiovascular surgery, prolonging recovery. A new clinical protocol explores if a specific anaesthesia strategy, using subanaesthetic esketamine, can prevent this serious delirium. This double-blind trial involves 778 older adults with Cardiovascular Disease, comparing esketamine to placebo. The goal is to establish if this approach improves outcomes, reducing delirium incidence and enhancing recovery for patients.
Abstract
Postoperative delirium (POD) is a common and serious complication in older adult patients undergoing cardiovascular surgery. Esketamine is known fo...
Neuroprotective Role of Ketamine in Reducing Neuroinflammation and Enhancing Neuroplasticity Against a Cortisol-Induced In Vitro Stress Model.
Molecular neurobiology – June 05, 2025
Summary
Groundbreaking research reveals how ketamine protects brain cells from stress-induced damage. High cortisol levels from chronic stress can trigger inflammation and harm neural connections. However, ketamine was found to shield neurons by blocking inflammatory signals (NF-κB and NLRP3), while boosting BDNF - a key protein that helps brain cells grow and form new connections. This explains ketamine's rapid antidepressant effects.
Abstract
Stress is widely recognized as a major environmental factor contributing to the development of mood disorders. In patients with Major Depressive Di...
Ketamine in Neurocritical Care: New Potentials and Perspectives.
Cureus – June 01, 2025
Summary
Ketamine, once controversial in brain injury treatment, emerges as a game-changing medication in neurocritical care. This versatile drug offers unique benefits: it provides effective sedation while protecting brain cells from damage. Beyond its primary role, ketamine shows promising anticonvulsant properties and maintains stable blood pressure in critical patients, making it invaluable for neurological emergencies.
Abstract
Ketamine is an intravenous hypnotic anesthetic that acts primarily by inhibiting N-methyl-D-aspartate (NMDA) receptors, leading to a range of effec...
Exploring the Neuroprotective and Neuropsychiatric Symptom Management Potential of Ketamine in Alzheimer's Disease.
Cureus – June 01, 2025
Summary
Beyond its use in anesthesia, ketamine shows surprising promise for Alzheimer's disease. Research in neuropharmacology suggests this NMDA receptor antagonist could modulate brain activity, enhancing synaptic function and reducing inflammation. Positive findings indicate ketamine's potential for managing challenging neuropsychiatric symptoms like depression and agitation often seen in Alzheimer's dementia, pointing to a new path for ketamine Alzheimer's treatment.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, synaptic dysfunction, and neuroinflammatio...
Esketamine mitigates endotoxin-induced hippocampal injury by regulating calcium transient and synaptic plasticity via the NF-α1/CREB pathway.
Neuropharmacology – May 15, 2025
Summary
Breakthrough research reveals how esketamine protects brain cells during severe infections. This powerful medication helps maintain healthy brain function by regulating calcium signals and preserving vital neural connections. By activating specific pathways in hippocampal neurons, esketamine reduces inflammation, enhances synaptic plasticity, and protects cognitive abilities. The findings demonstrate its potential as a treatment for septic encephalopathy.
Abstract
Esketamine (ES) has been shown to confer neuroprotection partly by exerting anti-inflammation, alleviating oxidative stress, enhancing neuronal vit...
Effect of Ketamine Analgosedation on Neurological Outcome in patients with Severe Traumatic Brain Injury: A Randomized Controlled Pilot Study.
Neurocritical care – May 13, 2025
Summary
Ketamine, unlike other pain medications, can maintain blood pressure in brain-injured patients. In a groundbreaking trial, researchers explored ketamine analgosedation in patients with severe traumatic brain injury. While the drug temporarily improved blood pressure and reduced intracranial pressure, long-term neurological outcomes were similar between treated and untreated groups. However, patients receiving ketamine needed fewer blood pressure medications.
Abstract
Most of the sedative and analgesic drugs used in patients with head injury cause a dose-dependent decrease in blood pressure, which may further wor...
Ayahuasca reverses ischemic stroke-induced neuroinflammation and oxidative stress.
Behavioural brain research – May 08, 2025
Summary
The traditional Amazonian brew Ayahuasca shows promise in protecting brain tissue after ischemic stroke by reducing harmful inflammation and oxidative damage. Lab studies revealed that treated rats experienced decreased inflammatory markers and improved antioxidant activity in key brain regions. The brew's neuroprotective effects were most notable in the prefrontal cortex and hippocampus, suggesting potential therapeutic value for stroke recovery.
Abstract
Ischemic stroke is a leading cause of death and disability worldwide. Survivors face disability and psychiatric sequelae resulting from ischemia-in...
The Role of microRNA in Anaesthetics-induced Brain Injury: A Narrative Review.
Turkish journal of anaesthesiology and reanimation – May 08, 2025
Summary
Small molecules in our cells may hold the key to making anaesthesia safer for developing brains. Recent findings show that microRNAs play a crucial role in how anaesthetic agents affect brain cells, particularly in young children. These molecules can either protect neurons or contribute to their damage. Understanding their function helps doctors develop safer anaesthesia protocols and protect vulnerable patients from neurotoxicity.
Abstract
Anaesthetics are commonly used agents during medical interventions and surgeries. Exposure to anaesthetic agents in late intrauterine life or early...
Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.
Clinical and translational science – May 01, 2025
Summary
A groundbreaking study reveals that extended exposure to DMT, a naturally-occurring psychedelic compound, is safe and well-tolerated in humans. Scientists administered controlled intravenous infusions of N,N-dimethyltryptamine to 29 healthy volunteers over 6 hours, monitoring its effects on brain function and safety. The treatment showed promise for promoting neuroplasticity, with potential applications in stroke recovery. Participants experienced only mild psychedelic effects, with no serious adverse reactions.
Abstract
The serotonergic psychedelic N,N-dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which it may exert neuropr...
Esketamine alleviates cognitive impairment signs induced by modified electroconvulsive therapy in a depression rat model via the KLF4/p38 MAPK pathway.
Journal of affective disorders – May 01, 2025
Summary
Promising breakthrough: Esketamine shows potential to protect brain function during electroconvulsive therapy for depression. The drug helps preserve memory and thinking abilities by activating protective pathways in the brain. Lab tests revealed it shields nerve cells while maintaining the therapy's antidepressant benefits.
Abstract
Depression is a common and serious psychiatric disorder with significant impacts on individuals. Modified electroconvulsive therapy (MECT) is an es...
Exploring DMT: Endogenous role and therapeutic potential.
Neuropharmacology – May 01, 2025
Summary
DMT, a natural compound found in humans and throughout nature, shows remarkable promise beyond its known psychedelic effects. Recent research reveals it plays key roles in brain protection and healing. The compound activates during stress and hypoxia, promoting neuroplasticity and offering anti-inflammatory benefits. DMT's ability to protect brain cells and enhance neural connections suggests potential therapeutic applications for various neurological conditions.
Abstract
N,N-Dimethyltryptamine (DMT) is a naturally occurring amine and psychedelic compound, found in plants, animals, and humans. While initial studies r...
Repeated administration of esketamine ameliorates mechanical allodynia in mice with chemotherapy-induced peripheral neuropathy: A role of gut microbiota and metabolites.
Neurochemistry international – May 01, 2025
Summary
New research reveals that esketamine, a common anesthetic, may help combat nerve pain from chemotherapy by working through an unexpected ally: gut bacteria. Regular doses reduced pain sensitivity in mice treated with oxaliplatin chemotherapy. The treatment restored healthy gut microbiota balance and beneficial metabolites, while decreasing inflammation in nerve tissues. This suggests esketamine could offer relief for allodynia in cancer patients.
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) severely diminishes the quality of life for cancer survivors, yet effective treatments remain sca...
Ayahuasca Pretreatment Prevents Sepsis-Induced Anxiety-Like Behavior, Neuroinflammation, and Oxidative Stress, and Increases Brain-Derived Neurotrophic Factor.
Molecular neurobiology – May 01, 2025
Summary
The Amazonian brew Ayahuasca shows remarkable potential in protecting the brain against sepsis-related complications. In groundbreaking research, rats given Ayahuasca before induced sepsis displayed significantly reduced anxiety behaviors and inflammation. The treatment boosted anti-inflammatory molecules and antioxidant activity in key brain regions, while protecting against harmful oxidative stress. These findings suggest powerful neuroprotective benefits.
Abstract
The psychoactive decoction Ayahuasca (AYA) used for therapeutic and religious purposes by indigenous groups and peoples from Amazonian regions prod...
[Treatment with psychedelics : potential benefits in Parkinson's disease].
Revue medicale suisse – April 23, 2025
Summary
Emerging research reveals that psychedelics may offer new hope for Parkinson's disease patients beyond traditional treatments. These compounds show potential in addressing both motor and non-motor symptoms while possibly protecting brain cells. They stimulate new neural connections, boost protective brain chemicals, and reduce inflammation. Early evidence suggests they could help manage depression and anxiety common in Parkinson's, while their brain-enhancing properties may slow disease progression.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their effica...
Ketamine for Critically Ill Patients with Severe Acute Brain Injury: A Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials.
Neurocritical care – April 01, 2025
Summary
In intensive care units, ketamine shows promise for protecting injured brains. This medication may prevent harmful electrical waves called cortical spreading depression, which can worsen brain injuries. Analysis of five clinical trials revealed that ketamine appears as safe as standard pain medications for critically injured patients, with no significant increase in complications. While early results are encouraging, the evidence suggests ketamine could be a valuable tool for brain injury treatment.
Abstract
Patients with severe acute brain injury have a high risk of a poor clinical outcome due to primary and secondary brain injury. Ketamine reportedly ...
Lithium attenuates ketamine-induced long-term neurotoxicity through DISC1-mediated GSK-3β/β-catenin and ERK/CREB pathways.
Toxicology letters – April 01, 2025
Summary
While ketamine is vital in pediatric anesthesia, its repeated use can harm developing brains. Researchers found that lithium can protect against ketamine's toxic effects on nerve cells. The study revealed that lithium activates protective pathways in the brain, specifically the GSK-3β/β-catenin and ERK/CREB systems, by boosting DISC1 protein levels. This discovery offers a promising way to make ketamine safer for young patients.
Abstract
Ketamine, an antagonist of N-methyl-D-aspartate receptor, is extensively employed in pediatric anesthesia. Multiple studies have shown that repeate...
Prophylactic Ketamine: Current Knowledge and Future Directions.
Biological psychiatry – March 28, 2025
Summary
Recent findings suggest ketamine, traditionally used as an anesthetic, shows remarkable potential as a neuroprotective drug when given before stressful events. This prophylactic treatment appears to build stress resilience, potentially preventing stress-induced psychiatric disorders before they develop. Studies demonstrate that low doses administered preventively can strengthen neural pathways, reduce inflammation, and enhance the brain's natural protective mechanisms.
Abstract
The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been incre...
N-Acetylcysteine Mitigates Ketamine Neurotoxicity in Young Rats by Modulating ROS-Mediated Pyroptosis and Ferroptosis.
Molecular neurobiology – March 20, 2025
Summary
A common anesthetic used in pediatric surgery, ketamine, can potentially harm developing brains. However, N-acetylcysteine (NAC), a powerful antioxidant, shows promise in preventing this damage. NAC works by blocking harmful cellular processes called ferroptosis and pyroptosis, which are triggered by excess reactive oxygen species (ROS). This protection helps preserve brain function and prevents cognitive impairment in young patients.
Abstract
Ketamine, an N-methyl-D-aspartate receptor antagonist with anesthetic and analgesic properties, is extensively utilized for the induction and maint...
Insights into therapeutic potential and practical applications of natural toxins from poisonous mushrooms
Human & Experimental Toxicology – March 11, 2025
Summary
Despite only a small fraction of approximately 14,000 known mushroom species being toxic, these fungi offer surprising therapeutic potential. Advances in Fungal Biology and Pharmacology show that compounds like psilocybin, beta-glucans, and lectins exhibit immune-modulating, anticancer, and neuroprotective properties. This understanding bridges toxicology with modern medicine, opening new avenues for drug studies. Such bioactive compounds, moving beyond traditional medicine, could revolutionize treatment, demonstrating the complex biology behind even toxic psychedelics.
Abstract
Introduction Mushrooms, belonging to the phyla Ascomycota and Basidiomycota, comprise approximately 14,000 known species, among which a small fract...
Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential.
Neuroscience – February 06, 2025
Summary
Nature's compounds offer promising solutions for brain health. Three plant-derived substances - Quercetin (found in fruits), Cannabidiol (from cannabis), and N,N-dimethyltryptamine (from various plants) - show remarkable potential in fighting neurodegenerative diseases. Each works uniquely: Quercetin as an antioxidant, Cannabidiol reduces inflammation, and DMT promotes brain plasticity. Together, they represent a powerful arsenal against neurological decline.
Abstract
Neurodegenerative diseases are a group of disorders characterized by progressive degeneration of discrete groups of neurons causing severe disabili...
Lutein Exerts Antioxidant and Neuroprotective Role on Schizophrenia-Like Behaviours in Mice.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience – February 01, 2025
Summary
A natural compound found in leafy greens shows promise in protecting brain function. Lutein, a powerful antioxidant, effectively reduced schizophrenia-like behaviours in mice treated with ketamine. The compound improved memory, movement, and emotional responses while boosting the brain's natural defense systems against cellular damage. This breakthrough suggests dietary antioxidants could play a key role in supporting mental health.
Abstract
Schizophrenia is an esteemed neuropsychiatric condition delineated by the manifestation which role of the N-methyl-D-aspartate receptor (NMDAR) is ...
Banisteriopsis caapi extract: Implications for neuroinflammatory pathways in Locus coeruleus lesion rodent model.
Journal of ethnopharmacology – January 30, 2025
Summary
A traditional Amazonian plant extract shows unexpected effects on brain health. Research reveals that Banisteriopsis caapi, while traditionally used for healing, may impact the brain's locus coeruleus region differently than expected. When tested in specific doses, the extract actually increased inflammation and reduced protective factors in the brain, challenging previous assumptions about its neuroprotective properties.
Abstract
Ayahuasca is a beverage obtained from the decoctions of Banisteriopsis caapi (Spruce ex Griseb.) Morton and Psychotria viridis Ruiz & Pav., used th...
Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
Both metformin and psilocybin show promising potential in protecting brain cells from Parkinson's disease damage. While metformin works by reducing cellular stress and preventing protein buildup, psilocybin promotes brain repair through serotonin pathway activation. This groundbreaking comparison reveals both compounds could offer prophylactic treatment options for neurodegenerative disease prevention.
Abstract
Treatment of Parkinson's disease (PD) has remained largely unchanged and focuses primarily on symptomatic relief through activation of dopaminergic...
The protective effect of DMT against neurodegeneration.
International review of neurobiology – January 01, 2025
Summary
The molecule dimethyltryptamine (DMT) shows remarkable potential for neuroprotection. Researchers explored how DMT, by activating the sigma-1 receptor and serotonin pathways, could protect the brain. Preclinical studies revealed DMT's ability to mitigate ischemia-reperfusion injury, a key factor in conditions like stroke and brain ischemia. This suggests DMT may offer therapeutic benefits against neurodegenerative disorders such as Alzheimer’s disease and amyotrophic lateral sclerosis, pointing to universal cellular protective mechanisms.
Abstract
This paper explores the therapeutic potential of DMT in neuroprotective strategies, particularly concerning ischemia-reperfusion injury (IRI) and n...